Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SGRY vs EHC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EHC Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

EHC Overall Winner 6-Pillar Tally: SGRY 1 – 5 EHC Matrix Metrics: SGRY 1 – 9 EHC

As of Nov 20, 2026, Encompass Health Corporation (EHC) is the stronger overall head-to-head candidate over Surgery Partners, Inc. (SGRY) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SGRY carries a Unified Composite Score of 29.6/100 (SELL) at $26.78 (N/M Forward P/E, 13.2% operating margin), whereas EHC carries 52.0/100 (HOLD) at $133.65 (19.4x Forward P/E, 18.4% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SGRY vs EHC
SGRY NASDAQ
Surgery Partners, Inc. Common Stock
Services-General Medical & Surgical Hospitals, Nec
$26.78
+0.34% 1D
Market Cap $3.5B
TTM Revenue $3.36B
Forward P/E N/M
Beta / 30D Vol 0.87β · 166% Vol
Unified Composite Score
29.6 / 100 SELL
Tech 50.0 Fund 24.0 Flow 56.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (30.5% over 20 days), RSI 84
RSI-14: 84.4 · SMA20: $24.97 · SMA50: $18.56
EHC NYSE Head-to-Head Winner
Encompass Health Corporation Common Stock
Services-Hospitals
$133.65
+1.04% 1D
Market Cap $13.0B
TTM Revenue $6.34B
Forward P/E 19.4x
Beta / 30D Vol -0.10β · 40% Vol
Unified Composite Score
52.0 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 54.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 50
RSI-14: 49.8 · SMA20: $135.78 · SMA50: $128.15

6-Pillar Scorecard Institutional Category Breakdown (SGRY 1 – 5 EHC)

Columns: Metric · SGRY · EHC
1. Valuation Multiples EHC
Forward P/E N/M 19.4x
Trailing P/E N/M 21.2x
PEG Ratio 1.66x 0.41x
EV / Revenue 1.9x 2.5x
2. Growth & Scale EHC
Revenue Growth (YoY) -0.8% +8.9%
Earnings Growth (YoY) +0.0% +21.6%
TTM Revenue (USD) $3.36B $6.34B
Market Cap $3.5B $13.0B
3. Profitability & Quality EHC
Gross Margin 22.2% 44.1%
Operating Margin 13.2% 18.4%
Net Profit Margin -2.6% 10.2%
Return on Equity (ROE) 2.1% 25.1%
4. Balance Sheet & Cash Flow EHC
Cash Generation (TTM) $203M $457M
Cash Flow Margin 6.0% 7.2%
Net Cash / Leverage $2.96B Net Debt (1.99x D/E) $2.73B Net Debt (1.05x D/E)
Dividend Yield None (0.00%) 0.58%
5. Options & Positioning SGRY
Options Structure Phase SURGE CONSOLIDATION
Current IV / %ile 62.1% (34th %ile) 27.0% (8th %ile)
Put/Call OI Skew N/A 0.25x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat EHC
OpEx & R&D Intensity 9.0% of Rev ($302M) 25.7% of Rev ($1.63B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Medical Care Facilities Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SGRY (1) vs EHC (9)
Institutional Metric SGRY EHC Criterion Row Edge
Market Capitalization
Scale
$3.5B $13.0B Larger Scale EHC
Trailing P/E Ratio
Valuation
N/M 21.2x Lower Multiple EHC
Forward P/E Ratio
Valuation
N/M 19.4x Lower Multiple EHC
Revenue Growth (YoY)
Growth
-0.8% +8.9% Higher Growth EHC
Operating Margin (TTM)
Profitability
13.2% 18.4% Higher Margin EHC
Net Profit Margin
Profitability
-2.6% 10.2% Higher Margin EHC
Return on Equity (ROE)
Capital Efficiency
2.1% 25.1% Higher ROE EHC
52-Week Range Position
Momentum
97% ($11–$27) 80% ($93–$144) Stronger Trend SGRY
Beta / 30D Volatility
Risk Regime
0.87β · 166% Vol -0.10β · 40% Vol Lower Realized Risk EHC
Unified Institutional Score
Composite Signal
29.6 / 100 (SELL) 52.0 / 100 (HOLD) Higher Composite EHC
Trailing 12M Revenue (USD)
Operating Scale
$3.36B $6.34B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
22.2% 44.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.66x PEG · 1.9x EV/Rev 0.41x PEG · 2.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$203M ($2.96B Net Debt (1.99x D/E)) $457M ($2.73B Net Debt (1.05x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SGRY +62.37 pp
SGRY: +68.43% · EHC: +6.06%
3M Horizon SGRY +81.44 pp
SGRY: +91.97% · EHC: +10.53%
6M Horizon SGRY +72.52 pp
SGRY: +99.85% · EHC: +27.33%
1Y Horizon SGRY +51.04 pp
SGRY: +70.46% · EHC: +19.42%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SGRY Revenue EHC Revenue SGRY Op. Margin EHC Op. Margin Margin Leader
FY2018 $1.77B $4.28B 4.4% 13.0% EHC
FY2019 $1.83B $4.61B 12.9% 13.3% EHC
FY2020 $1.86B $3.57B 9.8% 15.8% EHC
FY2021 $2.23B $4.01B 13.6% 13.9% EHC
FY2022 $2.54B $4.35B 13.6% 12.4% SGRY
FY2023 $2.74B $4.80B 12.0% 7.3% SGRY
FY2024 $3.11B $5.37B 11.2% 8.5% SGRY
FY2025 $3.31B $5.94B 11.8% 9.5% SGRY

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SGRY SURGE
5d in phase · OBV NEUTRAL
Current IV 62.1%
IV Percentile 34th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SGRY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EHC CONSOLIDATION
73d in phase · OBV DISTRIBUTION
Current IV 27.0%
IV Percentile 8th %ile
Put/Call OI Skew 0.25x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact EHC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SGRY Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $3.5B market capitalization and 13.2% operating margin.
OpEx & R&D Reinvestment 9.0% of Rev ($302M)
90D Engineering Disclosures 0 Published
EHC Moat Profile Scale & Operating Efficiency Moat
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $13.0B market capitalization and 18.4% operating margin.
OpEx & R&D Reinvestment 25.7% of Rev ($1.63B)
90D Engineering Disclosures 0 Published

Investor FAQ SGRY vs EHC Key Questions & Quantitative Answers

As of Nov 20, 2026, Encompass Health Corporation (EHC) is the stronger overall head-to-head candidate over Surgery Partners, Inc. (SGRY) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SGRY carries a Unified Composite Score of 29.6/100 (SELL) at $26.78 (N/M Forward P/E, 13.2% operating margin), whereas EHC carries 52.0/100 (HOLD) at $133.65 (19.4x Forward P/E, 18.4% operating margin). Technically, SGRY sits in a Markup phase (RSI 84.4, SURGE options structure) and EHC sits in a Neutral phase (RSI 49.8, CONSOLIDATION options structure).

EHC leads the Growth & Scale pillar: SGRY posts -0.8% YoY revenue growth and +0.0% YoY earnings growth on $3.36B TTM revenue (22.2% gross margin, 13.2% operating margin), compared with EHC at +8.9% YoY revenue growth and +21.6% YoY earnings growth on $6.34B TTM revenue (44.1% gross margin, 18.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SGRY cumulative revenue shifted +87.0% while EHC shifted +38.8%. In operating R&D and SG&A reinvestment, SGRY deploys 9.0% of Rev ($302M) (0 90-day corporate R&D disclosures) versus 25.7% of Rev ($1.63B) (0 disclosures) for EHC.

EHC screens cheaper on headline valuation multiples. SGRY trades at N/M Forward P/E, N/M Trailing P/E, 1.66x PEG, and 1.9x EV/Revenue (6.0% FCF margin), whereas EHC trades at 19.4x Forward P/E, 21.2x Trailing P/E, 0.41x PEG, and 2.5x EV/Revenue (7.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SGRY (2.1% ROE) versus EHC (25.1% ROE) capital efficiency.

In options market volatility and institutional positioning, SGRY carries 62.1% implied volatility (34th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.87β · 166% Vol realized risk). By comparison, EHC carries 27.0% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.25x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.10β · 40% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.